KOAGULASI

KEY CONCEPTS

1 IV replacement with recombinant or plasma-derived

products to treat or prevent bleeding is the primary
treatment of hemophilia.
2 Patients with type 1 von Willebrands disease (vWD)
unresponsive to desmopressin, patients with types 2 and
3 vWD, and major surgery patients require replacement
therapy with plasma-derived intermediate- and
high-purity factor VIII, virus-inactivated factor VIII
concentrate containing von Willebrands factor (vWF).
3 The primary treatment of recessively inherited
coagulation disorders (RICDs) is single-donor freshfrozen
plasma (FFP) that contains all coagulation factors.
4 The cornerstone of the management of disseminated
intravascular coagulation (DIC) is aggressive treatment
of the underlying primary illness. Supportive measures
may be used as necessary; however, owing to the
heterogeneity of the DIC etiology, treatment should
be guided by predominant symptoms (bleeding or
clotting).